Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials

Often, patients with primary immunodeficiency diseases (PID), which are marked by the absence or loss of functional antibodies, require lifelong treatment with immunoglobulin (IG) replacement therapy administe...

Source: BMC Immunology - May 4, 2020 Category: Allergy & Immunology Authors: Lisa M. Meckley, Yanyu Wu, Diane Ito, Todd Berner, Barbara McCoy and Leman Yel Tags: Research article Source Type: research